Compositions and methods for inhibition of the JAK pathway
View Patent ↗The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
1. A method of inhibiting an activity of a JAK kinase, comprising contacting the JAK kinase with a compound of formula I effective to inhibit an activity of the JAK kinase, wherein the compound of formula I has a structure of:
wherein:
p is 0, 1, 2, or 3;
q is 0, 1, 2, or 3;
X is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, —C(O)N(R 4 )R 5 , cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkynyl or substituted cycloalkynyl;
Y is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene;
R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
each R 2 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, —C(O)N(R 4 )R 5 , nitro or halo;
each R 3 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro or halo;
each R 4 independently is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen immediately adjacent to R 5 is anionic; or
R 4 and R 5 together with the intervening atom or atoms bound thereto, form a heterocyclyl or substituted heterocyclyl group;
each R 5 independently is hydrogen, alkyl, substituted alkyl, amino, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxyl, carboxyl ester or acyl;
R 6 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 6 is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene, linking the nitrogen bearing R 6 and the ring bearing Y
R 7 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl;
R 8 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 7 and R 8 together, with nitrogen to which they are bound, form a heterocyclyl or substituted heterocyclyl group;
wherein at least one of R 7 and R 8 is non-hydrogen; and
each of R 6 , R 7 , and R 8 optionally are M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen bearing M + is anionic.
2. A method of inhibiting an activity of a JAK kinase, comprising contacting in vitro a JAK3 kinase with a compound of formula I effective to inhibit an activity of the JAK3 kinase, wherein the compound of formula I has a structure of:
wherein:
p is 0, 1, 2, or 3;
q is 0, 1, 2, or 3;
X is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, —C(O)N(R 4 )R 5 , cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkynyl or substituted cycloalkynyl;
Y is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene;
R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
each R 2 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, —C(O)N(R 4 )R 5 , nitro or halo;
each R 3 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro or halo;
each R 4 independently is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen immediately adjacent to R 5 is anionic; or
R 4 and R 5 together with the intervening atom or atoms bound thereto, form a heterocyclyl or substituted heterocyclyl group;
each R 5 independently is hydrogen, alkyl, substituted alkyl, amino, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxyl, carboxyl ester or acyl;
R 6 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 6 is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene, linking the nitrogen bearing R 6 and the ring bearing Y
R 7 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl;
R 8 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 7 and R 8 together, with nitrogen to which they are bound, form a heterocyclyl or substituted heterocyclyl group;
wherein at least one of R 7 and R 8 is non-hydrogen; and
each of R 6 , R 7 , and R 8 optionally are M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen bearing M + is anionic.
3. The method of claim 1 , wherein the compound is administered in combination with, or adjunctively to, a compound or a pharmaceutical composition that inhibits Syk kinase with an IC 50 of less than 10 μM.
4. A method of treating or preventing allograft transplant rejection in a transplant recipient by inhibiting an activity of a JAK kinase, comprising administering to the transplant recipient a compound of formula I effective to treat or prevent the rejection, wherein the compound of formula I has a structure of:
wherein:
p is 0, 1, 2, or 3;
q is 0, 1, 2, or 3;
X is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, —C(O)N(R 4 )R 5 , cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkynyl or substituted cycloalkynyl;
Y is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene;
R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
each R 2 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, —C(O)N(R 4 )R 5 , nitro or halo;
each R 3 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro or halo;
each R 4 independently is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen immediately adjacent to R 5 is anionic; or
R 4 and R 5 together with the intervening atom or atoms bound thereto, form a heterocyclyl or substituted heterocyclyl group;
each R 5 independently is hydrogen, alkyl, substituted alkyl, amino, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxyl, carboxyl ester or acyl;
R 6 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 6 is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene, linking the nitrogen bearing R 6 and the ring bearing Y
R 7 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl;
R 8 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 7 and R 8 together, with nitrogen to which they are bound, form a heterocyclyl or substituted heterocyclyl group;
wherein at least one of R 7 and R 8 is non-hydrogen; and
each of R 6 , R 7 , and R 8 optionally are M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen bearing M + is anionic.
5. The method of claim 4 , wherein the compound is administered to a tissue or an organ prior to transplanting the tissue or the organ into the transplant recipient.
6. The method of claim 5 , wherein the rejection is acute rejection.
7. The method of claim 5 , wherein the rejection is chronic rejection.
8. The method of claim 5 , wherein the rejection is mediated by HVGR or GVHR.
9. The method of claim 5 , wherein the allograft transplant is a kidney, a heart, a liver or a lung transplant.
10. The method of claim 5 , wherein the compound is administered in combination with, or adjunctively to, another immunosuppressant.
11. The method of claim 10 , wherein the immunosuppressant is cyclosporine, tacrolimus, sirolimus, an inhibitor of IMPDH, mycophenolate, mycophenolate mofetil, an anti-T-Cell antibody or OKT3.
12. A method of treating a Type IV hypersensitivity reaction by inhibiting a JAK kinase, comprising administering to a subject a compound of formula I effective to treat or prevent the hypersensitivity reaction, wherein the compound of formula I has a structure of:
wherein:
p is 0, 1, 2, or 3;
q is 0, 1, 2, or 3;
X is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, —C(O)N(R 4 )R 5 , cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkynyl or substituted cycloalkynyl;
Y is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene;
R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
each R 2 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, —C(O)N(R 4 )R 5 , nitro or halo;
each R 3 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro or halo;
each R 4 independently is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen immediately adjacent to R 5 is anionic; or
R 4 and R 5 together with the intervening atom or atoms bound thereto, form a heterocyclyl or substituted heterocyclyl group;
each R 5 independently is hydrogen, alkyl, substituted alkyl, amino, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxyl, carboxyl ester or acyl;
R 6 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 6 is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene, linking the nitrogen bearing R 6 and the ring bearing Y
R 7 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl;
R 8 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 7 and R 8 together, with nitrogen to which they are bound, form a heterocyclyl or substituted heterocyclyl group;
wherein at least one of R 7 and R 8 is non-hydrogen; and
each of R 6 , R 7 , and R 8 optionally are M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen bearing M + is anionic.
13. A method of treating dry eye syndrome, uveitis, allergic conjunctivitis, glaucoma or rosacea, comprising administering to a subject a compound of formula I effective to treat the dry eye syndrome, uveitis, allergic conjunctivitis, glaucoma or rosacea, wherein the compound of formula I has a structure of:
wherein:
p is 0, 1, 2, or 3;
q is 0, 1, 2, or 3;
X is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted amino, carboxyl, carboxyl ester, —C(O)N(R 4 )R 5 , cyano, halo, nitro, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkynyl or substituted cycloalkynyl;
Y is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene;
R 1 is hydrogen, alkyl, substituted alkyl, cycloalkyl or substituted cycloalkyl;
each R 2 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, —C(O)N(R 4 )R 5 , nitro or halo;
each R 3 independently is alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aryl, substituted aryl, aryloxy, substituted aryloxy, cyano, cycloalkyl, substituted cycloalkyl, cycloalkoxy, substituted cycloalkoxy, heteroaryl, substituted heteroaryl, heteroaryloxy, substituted heteroaryloxy, heterocyclyl, substituted heterocyclyl, heterocyclyloxy, substituted heterocyclyloxy, aminoacyl, aminoacyloxy, carboxyl, carboxyl ester, carbonate ester, nitro or halo;
each R 4 independently is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, carboxyl, carboxyl ester, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen immediately adjacent to R 5 is anionic; or
R 4 and R 5 together with the intervening atom or atoms bound thereto, form a heterocyclyl or substituted heterocyclyl group;
each R 5 independently is hydrogen, alkyl, substituted alkyl, amino, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxyl, carboxyl ester or acyl;
R 6 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 6 is a straight or branched chain C 1-6 alkylene group, cycloalkylene or substituted cycloalkylene, linking the nitrogen bearing R 6 and the ring bearing Y
R 7 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl;
R 8 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl or acyl; or
R 7 and R 8 together, with nitrogen to which they are bound, form a heterocyclyl or substituted heterocyclyl group;
wherein at least one of R 7 and R 8 is non-hydrogen; and
each of R 6 , R 7 , and R 8 optionally are M + , wherein M + is K + , Na + , Li + or + N(R 9 ) 4 , wherein each R 9 independently is hydrogen or alkyl, and the nitrogen bearing M + is anionic.